Search

This EHNS–ESMO–ESTRO Clinical Practice Guideline provides key recommendations for managing SCCHN. It covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. Opportunities for personalised medicine in SCCHN are also discussed. All recommendations were compiled by a multidisciplinary group of experts from different institutions and countries. Recommendations are based on available clinical evidence and the collective expert opinion of the authors.

OBJECTIVES Chronic kidney disease (CKD) is a key risk factor in patients undergoing transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR). We analysed the impact of estimated glomerular filtration rate (eGFR) and CKD stages on their mid-term survival. METHODS Data from 29 893 patients enrolled in the German Aortic Valve registry from January 2011 to December 2015 receiving TAVI (n = 12 834) or SAVR (n = 17 059) at 88 sites were included. The impact of renal impairment, as measured by eGFR and CKD stages, was investigated. The primary end-point was 1-year cumulative all-cause mortality. RESULTS Higher CKD stages were significantly associated to lower in-hospital, 30-day- and 1-year survival rates. Both TAVI- and SAVR-treated patients in CKD 3a, 3b, 4 and 5 stages showed significant and gradually increasing HR values for 1-year all-cause mortality. The same trend persisted in multivariable analysis, although HR values for CKD 3a and 5 did not reach significance in TAVI patients, whereas CKD 4 + 5 did not reach statistical significance in SAVR. Likewise, eGFR as a continuous variable was a significant predictor for 1-year mortality, with the best cut-off points being 47.4 ml/min/1.73 m2 for TAVI and 59.8 ml/min/1.73 m2 for SAVR. Significant 8.6% and 9.0% increases in 1-year mortality were observed for every 5-ml reduction in eGFR for TAVI and SAVR, respectively. CONCLUSIONS CKD ≥3b and CKD ≥3a are the independent major risk factors for mortality in patients undergoing TAVI and SAVR, respectively. In the overall population of patients with severe aortic stenosis, an appropriate stratification based on CKD substage may contribute to a better selection of patients suitable for such therapies.

This EHNS-ESMO-ESTRO Clinical Practice Guideline provides key recommendations for managing SCCHN. It covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. Opportunities for personalised medicine in SCCHN are also discussed. All recommendations were compiled by a multidisciplinary group of experts from different institutions and countries. Recommendations are based on available clinical evidence and the collective expert opinion of the authors.

The Open Science Policy of the Friedrich-Alexander-Universität Erlangen Nürnberg (FAU) gives FAU members guidance and recommendations for opening up academic and scientific teaching, learning, communication and research processes. The Open Science Policy replaces the Open Access Policy agreed by the Executive Board on 22/03/2011. The Open Science Policy will be evaluated and adjusted every three years. version 1 of 2011-03-22 (Open Access Policy, in German) version 2 of 2021-10-13 (Open Science Policy, in German and English)

The International Committee on Systematics of Prokaryotes has held an electronic discussion on proposals to amend the International Code of Nomenclature of Prokaryotes in order to allow the use of gene sequence data as type. The scientific discussion is reported. Subsequently members of the International Committee on Systematics of Prokaryotes voted on these proposals, which were rejected.

Professor Darrell Whitley has become one of the 2019 ACM Fellows "Recognized for Far-Reaching Accomplishments that Define the Digital Age". Members of the SIGEVO executive board sent Darrell a set of questions.

International audience; Evidence that enables us to identify, assess, and access the small airways in asthma and chronic obstructive pulmonary disease (COPD) has led INTERASMA (Global Asthma Association) and WAO to take a position on the role of the small airways in these diseases. Starting from an extensive literature review, both organizations developed, discussed, and approved the manifesto, which was subsequently approved and endorsed by the chairs of ARIA and GA2LEN. The manifesto describes the evidence gathered to date and defines and proposes issues on small airway involvement and management in asthma and COPD with the aim of challenging assumptions, fostering commitment, and bringing about change. The small airways (defined as those with an internal diameter